Clinical Trial: A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab combined with tislelizumab plus chemotherapy for esophageal squamous cell carcinoma (China)

Posted On: 2026-08-11

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab combined with tislelizumab plus chemotherapy for esophageal squamous cell carcinoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129512

Registration Time: 2026/08/05

Type: Interventional study

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=327204

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab combined with tislelizumab plus chemotherapy for esophageal squamous cell carcinoma (China)